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ABSTRACT
Introduction: Oromucosal films, comprising mucoadhesive buccal films (MBFs) and orodispersible films
(ODFs), are considered patient-centric dosage forms. Target groups are patients with special needs.
Various active pharmaceutical ingredients have been shown to be suitable for oromucosal film produc-
tion. A shift is seen in the production techniques, from conventional solvent casting to printing
techniques.
Areas covered: In this review, the patient acceptability of oromucosal films is discussed. An overview is
given of the small molecule drugs, biopharmaceuticals and herbal extracts that have been incorporated
so far. Finally, the current state of 2D and 3D printing techniques for production purposes is discussed.
Expert opinion: The patient-centric features are important for the further development and acceptance
of this oral solid dosage form. Oromucosal films perfectly fit in the current attention for personalized
medicine. Both MBFs and ODFs are intended for either a local or a systemic effect. For buccal
absorption, sufficient mucoadhesion is one of the most important criteria an oromucosal film must
comply with. For the preparation, the solvent casting technique is still predominately used. Some
limitations of this production method can be tackled by printing techniques. However, these novel
techniques introduce new requirements, yet to be set, for oromucosal film preparation.
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1. Introduction
Oromucosal films comprise mucoadhesive buccal films (MBFs)
and orodispersible films (ODFs). They are defined as single – or
multilayer sheets of suitable material [1]. MBFs are placed in
the mouth and attach to the buccal mucosa. MBFs can be
used for the treatment of systemic or local diseases. In sys-
temic therapy, the active pharmaceutical ingredient (API) is
absorbed via the mucosa, bypassing the gastrointestinal tract,
and/or swallowed with saliva [2]. In the treatment of local
diseases, MBFs are favorable over oral gels or oral ointments,
as they have a longer retention time in the mouth and there-
fore cannot be washed away easily with saliva [3]. ODFs are
placed onto the tongue and disperse rapidly [1]. The API is
mainly swallowed with saliva following the gastrointestinal
route for absorption [2]. ODFs are commonly used for the
treatment of systemic disorders.
Oromucosal films are considered patient-centric dosage
forms with high patient acceptability [2]. Patient acceptability
has been defined by the European Medicines Agency as the
ability and willingness to take a medicinal product as intended
[4]. Patient acceptability has now become a key parameter to
guide the drug product development in order to ensure
adherence to the medicinal treatment and to minimize med-
ication errors. Characteristics such as ease of transportability
and handling, thinness and flexibility, dose flexibility, and the
possibility of taking them with no or just little water make
oromucosal films suitable drug-delivery systems for patient
populations with special needs [2,5]. In particular, patients
(older) affected by dysphagia [2], infants and young children
[6] and uncooperative [7] or nauseated/vomiting patients [8]
may benefit from the patient-centric nature of these dosage
forms. The rapid disintegration and/or the mucoadhesive
properties of oromucosal films ensure that the formulation
cannot be easily spat out [9]. In addition, oromucosal films
can be taken without the need of any manipulation steps by
following simple instructions, which makes them convenient
for administration in any circumstances, and also for patients
who may struggle to follow preparation instructions.
Drug compounds of different nature can be incorporated
into an oromucosal film: low molecular weight APIs which are
either highly water-soluble or poorly water-soluble, biophar-
maceuticals, or herbal plant extracts [2,10,11]. Some oromuco-
sal formulations ensure a fast absorption of the API, and
therefore a rapid onset of action that can be advantageous
in emergency circumstances [5,9]. Conversely, a controlled or
delayed drug release from oromucosal formulations [12,13]
might represent a more convenient administration method
than multiple doses.
A main hurdle in oromucosal film preparation is the limited
drug load that can be contained. A relatively simple method
to increase the drug load is to increase the surface area and/or
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the thickness of the film. This may, however, negatively influ-
ence patient acceptance [2]. Another option is the use of
multi-layered oromucosal films. These films can be, for exam-
ple be prepared using the solvent casting method [14,15]. The
solvent casting method is up to day the most used prepara-
tion technique for oromucosal film preparations. In short, all
the excipients are dissolved in a suitable solvent (usually
water). The solution is cast, dried, and cut into the desired
size. Recently, printing techniques have been proposed for the
preparation of oromucosal films. Figure 1 provides an over-
view of the characteristics of oromucosal films.
This review focuses on the patient-centric features of oro-
mucosal films for systemic and local drug delivery via the oral
cavity. Further, an overview is given of APIs recently incorpo-
rated into oromucosal films. Finally, it addresses novel printing
techniques for the manufacturing of oromucosal films. These
techniques can be used for small and large-scale production.
2. Patient-centric features of oromucosal films
2.1. Patient acceptability
The impact that a medicinal product design can have on
patient acceptability requires assessment, and novel meth-
odologies are being proposed and tested [4,6]. The number
of scientific publications on the assessment of patient accept-
ability for medicinal products and dosage forms is rapidly
increasing [6,16,17].
Depending on whether oromucosal films belong to the
MBF or the ODF family, patient-centric features can be
described. As the residence time of MBFs is long, they must
be thin, soft and flexible in order to avoid irritation to the
mucosal tissue. The same features also make them comforta-
ble to keep in the mouth. Several formulation parameters can
influence some of the acceptability attributes specific to buc-
cal films. For example, the residence time in the mouth
depends, among other factors, on the mucoadhesive strength
of the film [18]. Various test methods to determine the
mucoadhesive strength in vitro (e.g. using a texture analyzer,
rheology, surface tensiometer) and in vivo (in volunteers) were
reviewed by Woertz et al. [18]. Also, the film flexibility and
resistance to tear represent mechanical properties that can
determine the final characteristics of the dosage form, and
consequently its sensory attributes. These formulation para-
meters can be established by determining the folding endur-
ance or by measuring tensile strength and elongation at break
[2]. Sufficient mechanical properties will lead to a high quality
and robust product ensuring damage-free handling [13]. Such
acceptability attributes are heavily influenced by the type of
polymer or polymer blend forming the film matrix [12]. For
example, molecular weight of a certain type of polymer deter-
mines the disintegration time of the polymeric matrix and
thus the residence time of the buccal film. Also, the strength
of film mucoadhesion may among other factors depend on
the abundance of hydrogen-bonding groups of the polymer
[13]. Keeping the film pH within the physiological range can
also prevent irritation to the oral mucosa [19].
Rapid dissolution and the possibility of intake without the
aid of water make ODFs easy to administer. Moreover, ODFs
break down into soft particles upon disintegration, thus pre-
venting the patient from experiencing potential discomfort
due to the gritty nature of multiparticulates, or orodispersible
tablets (ODTs). The addition of sweeteners, flavors, and the
application of taste-masking technologies can considerably
improve the palatability of ODFs, making medicine adminis-
tration less imposing, particularly to children [2,6]. Finally, the
tendency of ODFs to stick to the mucosa immediately upon
placement can facilitate their application to uncooperative
patients and patients who due to their illness are unable to
take medication.
For MBFs and ODFs, a layered design can represent
a promising platform for fixed-dose combinations and for
controlled release [14,15]. This will result in lower dosing
frequency and thus lead to improved patient adherence and
compliance.
There is a limited availability of published literature on the
acceptability assessment of MBFs, however, evidence of high
Article highlights
● The patient-centric design of oromucosal films improves acceptability
in patient groups with special needs, such as the aging population
and children.
● Mucoadhesive buccal films and orodispersible films are suitable
dosage forms for the treatment of certain systemic as well as local
disorders.
● With oromucosal films, especially mucoadhesive buccal films, absorp-
tion of the active pharmaceutical ingredient through the oral mucosa
can be achieved.
● Oromucosal films might become a platform for the administration of
biopharmaceuticals in the oral cavity.
● The use of oromucosal films with prolonged release may improve
patient compliance and adherence due to the lower dosing
frequency.
● 2D and 3D printing are promising novel production techniques for
oromucosal films next to conventional solvent casting.
This box summarizes the key points contained in the article.
Oromucosal films
Multilayer design
• MBF: non dissolving backing layer
• MBF and ODF: fixed dose combinations,  prolonged drug release
Characteristics
• Rapid dissolution
• Stick to the mucosa
• Break down in soft particles
• Predominately systemic drug 
delivery
• API mainly swallowed with saliva
• Absorption via gastro intestinal 
tracts
Characteristics
• Long residence time in the 
mouth
• Sufficient mucoadhesion
• Local and systemic drug 
delivery
• API absorption mainly via the 
oral mucosa
• Increase of bioavailability
Mucoadhesive buccal films Orodispersible films
Preparation method
• Conventional solvent casting technique
• Novel printing techniques
Figure 1. Overview of the characteristics of oromucosal films.
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patient acceptability of ODFs is provided in several studies.
Different ODF formulations were assessed in vivo with regards
to swallowability, palatability, presence of residues in the mouth,
grittiness, taste-masking, mouth freshening, size, thickness, solu-
bility, disintegration time, and ease of administration [6,20–22].
The ‘gummy’ nature of disintegrating ODFs as a potentially dis-
advantage contributing to their mouthfeel and possibly to their
acceptability was reviewed by Krampe et al. [2].
The patient-centric design of ODFs was found to contribute
to the high acceptability observed in infants and preschool
children, and their carers [6]. Patient acceptability of ODFs was
found to be influenced by individual formulation attributes
such as ODF perceived stickiness and disintegration time [16]
and by non-formulation-related parameters such as the altera-
tion of the intended use, the subdivision of the dose intake,
the use of drink or food to facilitate administration, or the use
of restraint [17].
To sum up, patient acceptability of oromucosal film is
dependent on several parameters. For MBFs sufficient
mucoadhesion and a non-irritable texture of the film are key
factors. For ODFs, rapid dissolution and appropriate taste
masking are important. Finally, a layered design of oromucosal
films may contribute to less dosing frequency.
2.2. Local and systemic drug delivery
According to literature, both MBFs and ODFs are used for the
local and systemic delivery route, although the recent focus is
mainly on systemic administration.
Oromucosal films can be used for the treatment of various
disorders. These include cardiovascular disorders, pain disor-
ders, and mood or mental disorders (see Table 1).
Various (potent) APIs can be incorporated into oromucosal
films: water-soluble and poorly water-soluble small molecule
drugs, biopharmaceuticals and herbal plant extracts (examples
are shown in Table 1). The most common used polymers are
cellulose derivates, such as hypromellose and hydroxypropyl-
cellulose [2,39]. Furthermore, formulations with polyvinylalco-
hol are often mentioned in literature [9,40–45].
The incorporation of poorly water-soluble drugs is possible but
complying with the uniformity of content is challenging. Different
strategies for solubility improvement have been suggested, such
as the use of organic solvents (e.g. ethanol to improve the solubi-
lity of diazepam [46]) or the addition of solubility enhancers [47],
the use of organic acids to influence pH-dependent solubility [48],
the use of mesoporous silica nanoparticles as a carrier for poorly
water-soluble drugs (e.g. prednisolone) [49], and micronization of
the API to reduce its particle size [50]. Particle size reduction is an
often used method to improve the solubility of poorly water-
soluble APIs [51–56]. Krull et al. showed that the dissolution of
poorly water-soluble griseofulvin can be enhanced by using wet-
milled drug particles. These (nano)particles were incorporated into
a pullulan-based film [51] and hypromellose-based films [52,53].
Herbal plant extracts are frequently used as medicines for
the treatment of various diseases in Asian countries. The
development of oromucosal films containing curcumin [57],
cucurbitacin B [58], Acemella oleracea extract [59], and ODFs
with extracts of Lagerstroemia speciosa (L.) Pers., Phyllanthus
niruri L., Cinnamomum burmanii Blume, Zingiber officinale
Roscoe, and Phaleria macrocarpa Boerl [11] have been
reported.
The APIs are usually swallowed together with saliva and
follow the gastrointestinal route for absorption. On the other
hand, a relatively new delivery route for oromucosal films,
especially MBFs, is through the oral mucosa. The absorption
via the mucosa is mainly driven by passive diffusion across
the lipid membranes. Hydrophilic APIs will be transported
predominately via the paracellular pathway and lipophilic
APIs via the transcellular pathway [60]. The advantage is
that after absorption, the hepatic first pass metabolism is
largely bypassed and the API enters the systemic circulation
directly. Although the buccal mucosa may act as a barrier,
absorption via this route may lead to an increased bioavail-
ability [2] for APIs with low bioavailability after oral admin-
istration, for example zolmitriptan and duloxetine [61].
Gastric stasis in migraine may influence bioavailability.
Besides, absorption via the buccal mucosa circumvents the
degradation due to gastric enzymes or due to the acidic
environment of the stomach. A limiting factor is the perme-
ability for larger molecules (>500 kDa according to Lipinski’s
rule of five [62]), which can lead to challenges in formulation
development.
MBFs are available in a layered design that prevents dis-
solution of the drug inside the oral cavity but ensures mucosal
absorption [14]. Other multi-layered formulations enable the
release of multiple APIs in a sequential fashion [13]. The most
commonly used polymer in this case is ethyl cellulose [63].
Hypromellose [14] as well as the natural beeswax [64] can
alternatively be used as a slowly eroding shield. Another
example is the development of a bi-medicated bilayer MBF.
This MBF contains lidocaine in the outer side and diclofenac in
the inner side and is intended for the treatment of radiation-
induced oral mucositis [65].
Sufficient mucoadhesion is one of the most important criteria
which a film must comply with application into the oral cavity.
Typical polymers used as mucoadhesive components are gela-
tin, chitosan [66], pullulan [67], guar gum [68], xanthan gum [61],
sodium carboxymethylcellulose [69], hydroxypropylcellulose
[70] and sodium hyaluronate [71]. Various natural polysacchar-
ides show mucoadhesive properties such as psyllium [72], okra
[73] and certain rice varieties with a high amylose content [74].
The mucoadhesive properties of commonly used polymers
like chitosan can be increased by thiolation [75]. Naz et al.
described that thiolated films of fluconazole for buccal deliv-
ery increase the mucoadhesive strength significantly when
compared to corresponding, non-thiolated films. The strong
mucoadhesive properties of these thiolated polymers are due
to the formation of covalent bonds with mucus glycoproteins
[76]. Shiledar et al. showed that dimethyl sulfoxide, which is
well known for its cell toxicity, enhances the permeability
without any kind of buccal mucosal damage [61].
An increased amount of permeated drug can be reached using
liposomal formulations [77], nanoparticles [78], or nanofibers [70],
which are gaining high impact regarding the buccal transport
route [57]. Morales et al. developed MBFs embedded with insulin-
coated nanoparticles, which resulted in an enhanced permeation
of insulin through mucosa in comparison with an insulin control
solution in phosphate-buffered saline [78]. The insulin-coated
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nanoparticles were prepared with d,l valine and acid phthalate
buffer (pH 2.2) [78].
Mortazavian et al. revealed that the combination of applying
thiolation of chitosan as a mucoadhesive component in buccal
films and the incorporation of insulin nanoparticles further
increased permeation [75]. Through the use of nanoparticles
with biodegradable polymers such as poly(lactic-co-glycolic
acid), it was feasible to allow a slow release of antihypertensive
peptides through the buccal epithelium [68].
Products for mucosal drug delivery, which are already on the
pharmaceutical market, include Breakyl® (fentanyl buccal film) and
Belbuca® (buprenorphine buccal film). Breakyl® is available in dif-
ferent dosages of 200–1200 µg, whereby the dosage increase is
achieved by increasing the film area [79]. Belbuca® is available in
dosages from 75 to 900 µg. No information about the film area of
the different dosages is available [80].
MBFs and ODFs are, although mainly used in the treatment
of systemic disorders, also used in the treatment of local
disorders such as oral inflammatory diseases, cancer in the
oral cavity, or for local anesthesia.
Table 1 gives examples of the oromucosal films for local
and systemic treatment, respectively, that have been found in
literature over the past 5 years, and the beginning of 2019.
Various APIs were incorporated into oromucosal films. MBFs
were predominately developed for the treatment of local dis-
orders, whereas ODFs were predominately developed for the
treatment of systemic disorders.
2.2.1. Biopharmaceuticals
As biopharmaceuticals, e.g. vaccines, after oral intake are
prone to degradation by gastro-intestinal fluids, the buccal
or sublingual route may be a suitable alternative [81].
Literature reveals multiple preparation methods to improve
the stability and penetration of biopharmaceuticals with the
aim to increase their bioavailability. Tian et al. developed an
ODF based on a blend of trehalose and pullulan for protein
delivery [10]. Morales et al. developed insulin-coated nanopar-
ticles for insulin permeation through the mucosa [78], an ODF
containing a microparticulate measles vaccine formulation for
buccal delivery has been developed by Gala et al. [82], and an
ODF with probiotics has been developed by Heinemann et al.
[83]. Due to the very low log P value of biopharmaceuticals,
passive diffusion is limited. Hence, the main route for absorp-
tion of biopharmaceuticals upon buccal administration is via
the transcellular pathway, via receptor-mediate transport, and
via the paracellular pathway. However, the tight junctions
hamper the absorption of biopharmaceuticals with higher
molecular weights (>200 Da) [84].
In conclusion, oromucosal films may become a platform for
the administration of biopharmaceuticals with lower molecu-
lar weights in the oral cavity.
2.2.2. Permeation testing
The buccal mucosa acts as a natural barrier. Therefore, one
of the essential tools for the evaluation of MBFs intended for
systemic drug administration is permeation testing. In litera-
ture, various animal tissues have been used, which are sup-
posed to mimic the human buccal mucosa. Mostly used are
esophageal [40,85] and buccal porcine membranes [86] as
well as buccal membranes from chicken [87], sheep [61],
rabbit [88] and goat [76]. Investigations with cell cultures
are gaining popularity, as shown by experiments by Castro
et al. with cell TR146 lines [68] and Morales et al. with
tridimensional human buccal tissue (EpiOral) [78]. When
performing permeation tests, Franz diffusion cells are con-
ventionally used, which are modified sometimes according
to the specific use [87]. The permeation rate is analyzed
based on the flux determination by calculating the slope
of the resulting plot. A further evaluation method is the
determination of the apparent permeability which requires
the flux (J) over the concentration (co) [68].
The main disadvantage of permeation tests via animal
tissues is the high variability of the data. The storage condi-
tions of the tissue, the integrity and the viability of the tissue
are important parameters that should be monitored and
determined prior to use [89].
To date, no pharmacopoeia contains a standardized test to
measure permeation.
2.2.3. Prolonged drug release
Thus far, a number of oromucosal films with prolonged release
properties have been developed. The compliance and adher-
ence of the patient is substantially improved by a lower dos-
ing frequency. Some drugs have already succeeded in
achieving prolonged release (2–8 h) via MBFs and also in
increasing bioavailability, for example prednisolone [86],
ondansetron [71], griseofulvin [90] and doxepin [91].
Even though rapid disintegrating is the main feature of
ODFs, in particular cases prolonged drug release from ODFs
would also be beneficial, especially for patients with swallow-
ing deficiencies. Prolonged drug release from ODFs has been
achieved by incorporating drug-loaded matrix particles based
on Eudragit® RS and silicon dioxide [92]. In that study, the
matrix particles, with theophylline as a model drug, were
produced by hot melt extrusion (HME), and the ODFs were
subsequently produced by the solvent casting method. The
downside of this method was the inhomogeneous distribution
of the particles due to a large particle size distribution and
different particles shapes. To overcome this problem, micro-
pellets with microcrystalline cellulose and sodium carboxy-
methylcellulose were prepared. The researchers investigated
the incorporation of prolonged release small-size micropellets
into ODFs with diclofenac as a model drug [93]. After disin-
tegration of ODFs in the oral cavity, the incorporated matrix
particles or micropellets can be swallowed together with the
saliva after which the drug is slowly released in the gastro-
intestinal tract. Prolonged release can also be achieved by
using a drug – ion exchange resin complex. For this, Shang
et al. used betahistine as a model drug. Betahistine has unfa-
vorable characteristics for ODF production: it is very hygro-
scopic, has a short half time and a bitter taste. All these issues
were tackled by the drug – ion exchange resin complex.
Although the ODF was dissolved in the oral cavity, betahistine
was released in the gastrointestinal tract from the com-
plex [42].
For improving drug load and achieving sustained release of
poorly water-soluble fenofibrate, Kevadiya et al. developed
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a sandwiched film. This film contained a drug-loaded hydro-
philic layer between to hydrophobic layers. Sustained release
up to 480 min was achieved, depending on the thickness of
the inner layer. The control films without hydrophobic layer
released the API within 45 min [94].
3. Novel production techniques
Printing technologies have gained interest in pharmaceutical
manufacturing purposes. Many printing technologies exists
and are based on various different principles. The application
of printing requires investments in reliable printers and com-
petence in handling sophisticated tools (software) to enable
the design of drug-delivery systems. However, automated
systems with integrated quality control can be developed
even to be used at point-of-care. General challenges in apply-
ing printing techniques are related to the maximum applic-
able dose, choice, and development of a functional substrate,
development of suitable inks, interactions of substrate and ink
to name a few important ones. Examples of printers used for
pharmaceutical manufacturing are shown in Figure 2.
3.1. Pharmaceutical inkjet printing
Besides 3D printing, inkjet printing also referred to as 2D
printing, moved into the focus. Inkjet printing is
a contactless process of droplet deposition onto an appropri-
ate carrier substrate, classically a paper sheet or foil. In case of
drug printing, oromucosal films are the most reported sub-
strates in literature [41,95–98]. They resemble the usual types
of substrates and offer a higher surface for drug imprints
compared to tablets.
The printing fluid consists of the drug dissolved in
a suitable solvent or dispersed in a dispersant. As viscosity
and surface tension are the most important properties to be
considered to create a printable fluid, addition of one or more
excipients is usually required. Obviously, these excipients
should be non-toxic and of pharmaceutical grade, which limits
the application of inkjet printing. In inkjet printing, the ink
may also be formulated as a nanosuspension. The composition
of the nanosuspensions and the physicochemical properties of
the particles
(size, polydispersity, and net surface charge), particle con-
centration, excipient addition (surfactants), and solvent system
will have an impact on the performance and stability of the ink
formulation.
The main advantage of the inkjet technology is that the
required dosage can be precisely printed on demand and tai-
lored to the patients’ specific requirements by a community or
hospital pharmacist according to the prescription of the physi-
cian. There is no need to meet an exact wet film thickness as in
the solvent casting technique because the dosage is controlled
by the printing parameters, concentration of the printing fluid
and the number of layers. This avoids trial and error adjustments
of the wet film thickness or concentration of the polymer solu-
tions [99] to reach the desired content as it is the case when
solvent casting is used.
The predominantly used inkjet technique is the drop-on-
demand (DoD) technology where a drop is only ejected on
request. There are two implemented DoD printer driving
methods: thermal and piezoelectric method (see Table 2).
Liquid piezo-driven micro-dispensing systems may be also
applied as they have usually larger nozzle diameters and can
handle more viscous and higher particle-loaded fluids. (see
Table 2). In thermal DoD process, the drops are ejected by
pressure caused by an ink bubble due to rapid vaporization
after brief heat treatment. Only water-based printing fluids can
be used in this case. In piezoelectric systems, applied voltage
leads to deformation of the ink chamber walls and generates
a pressure wave ejecting drops. Solvent- and water-based
fluids can be printed.
Different types of microdispensers systems have been also
used to study the manufacturing of drug-delivery systems.
Bonhoeffer et al. used a piezo-actuated micro-valve to inves-
tigate the dispensing of drug nanosuspensions onto sub-
strates to make solid oral dosage forms. The micro-valve
system in question was been characterized regarding dispen-
sing behavior, mass flow, accuracy, and robustness. And the
study showed that adjusted from a few micrograms to several
milligrams with high accuracy is possible and that the fluid
properties, dispensing parameters of the micro-valve, and
steady state mass flow was correlated for low-viscous drug
nanosuspensions.) [102].
Oromucosal films can be prepared by inkjet printing non-
continuously for small batches (e.g. community or hospital
Figure 2. Examples of printers used for pharmaceutical manufacturing (left: piezoelectric inkjet printer PixDro LP 50, right: a dual syringe BioBots (Allevi) semi-solid
extrusion (SSE) printer).
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pharmacy) or continuously for larger scale (in hospital phar-
macy or pharmaceutical industry) [95].
As 2D printing is a new approach for dosage form produc-
tion there are some challenges to overcome. The main chal-
lenge is clogging of nozzles. If the required volume is not
ejected because of blockage, the target dose cannot be
reached. However, similar is the case when the calculated
drug content is not achieved because of a mismatch of theo-
retical and practical wet film thickness during solvent casting
of oromucosal films [103]. Furthermore, the drug has to be
stable in the printing fluid during production and storage as
well as in the polymer solution using the casting method.
Finally, inkjet printing is so far limited to low-dose applications
just like conventional manufactured film formulations.
The application of inkjet technology leads to different require-
ments for the oromucosal films as functional substrates. They
have to be stable enough for imprinting while avoiding disinte-
gration during the process, but should maintain their orodisper-
sible and/or mucoadhesive properties. The substrates can be
developed based on specific needs such as the absorptive cap-
ability and mechanical strength and, e.g. print quality if for
instance if high-resolution QR codes needs to be printed on the
substrates. The interaction between printing fluid and substrate
determines besides whether the drug get lost due to rebounding
effects [102], stays on the surface or penetrates inside the film
matrix. There is the possibility to use additional excipients like
mesoporous fumed silica to increase the absorptive properties of
the films [97]. Furthermore, the oromucosal preparations should
be sufficiently wetted by the applied printing fluid avoiding
irregularities. A new approach is to produce the films by electro-
spinning gaining a fibrous structure with high surface area [103].
Pre-coatings containing high molecular polyethylene glycol aim
at a better spreading of hydrophilic fluid on the films [98]. Edible
rice paper and icing sheets can be used instead of cast
films [104].
Crystallization behavior of the drugs after deposition on the
substrate should bemonitored during formulation development
as it may significantly influence the solubility, dissolution, and
handling. Amorphous-printed dosage forms were produced by
adding polymers to the printing fluid [105]. In this study, it was
also shown that the bigger the drop volume the higher is the
crystalline proportion because small drops dry faster and the
drug substance has less time for crystallization. The more print-
ing passes the higher was the amorphous ratio due to the
increasing amount of propylene glycol and higher solvation of
the drug [103,106]. With increased drug content, the recrystalli-
zation rate can increase and drug crystals can be formed on the
top of the oromucosal films [95].
Besides single-dosed medicines, there are further progresses
described in literature. Drug combinations were produced by
printing levothyroxine and liothyronine onto a drug-free ODF
[96]. Enalapril maleate was printed onto hydrochlorothiazide
containing ODFs [95] and lidocaine hydrochloride onto fibrous
gelatine substrates containing piroxicam [103].
With regard to security measure, a traceability system in
the form of QR codes was printed onto ODFs [97]. On the one
hand, drug loading and drug therapy safety are ensured and,
on the other hand, anti-counterfeiting and patients assign-
ment may be enabled by printed film products. Hereby, one
more future-oriented step would be done toward digitaliza-
tion and safety improvement of individualized medicine. In
Figure 3 examples are shown of printed oromucosal films,
with and without QR codes.
3.2. Roll-to-roll printing
Inkjet printing is, to date, the most utilized printing technol-
ogy to produce drug-loaded oromucosal films, however, other
printing techniques have also been explored. Flexographic
printing is a fast roll-to-roll printing method [107]. The phar-
maceutical ink is transferred from an anilox roller to the print-
ing cylinder. By applying a pressure between the printing
cylinder and the impression cylinder, the ink is printed onto
the polymer. Hypromellose-based drug-free ODFs were flexo-
graphically imprinted with either rasagiline or tadalafil [108].
Another study revealed an improved dissolution rate of the
poorly water-soluble drug piroxicam when flexographically
printing ODFs. This was probably due to the fact that pirox-
icam was in solution state [109]. The dose in ODFs prepared by
flexographic printing is adjustable and can be increased by
the number of applied printing cycles.
Flexographic printing can also be a production method of
choice for the conversion of nanosuspensions into solid
dosage forms [110].
3.3. Fuzed deposition modeling and semi-solid extrusion
printing
3D printing, also called additive manufacturing, is associated
with great flexibility regarding the size, geometry, and inner
Figure 3. Examples of oromucosal films prepared with printing techniques (left: SSE printed warfarin films (transparent films) and inkjet printed substrates (yellow
colorant in warfarin ink), right: QR code printed on substrates (blue placebo ink)).
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structure of the printed object [111]. 3D printing in the phar-
maceutical field has typically involved printing of, for example
personalized tablets, orodispersible tablets, and implants. But
the suitability to utilize 3D printing for the production of ODFs
has been explored. One type of 3D printing is extrusion-based
3D printing, which further can be divided into fuzed deposi-
tion modeling (FDM) and semi-solid extrusion (SSE) based 3D
printing. FDM 3D printing requires a drug-loaded feedstock
material, which typically is produced by means of HME. The
produced filament, with a specific diameter, is fed into the
FDM 3D printer. By the use of high temperatures, the thermo-
plastic material is melted and extruded through the nozzle,
and sequential layers of material are deposited to create the
pre-determined 3D structure designed using a computer-
aided design program. Ehtezazi et al. produced fast dissolving
single or multi-layered oromucosal films by means of FDM 3D
printing where polyethylene oxide-based solid films contain-
ing ibuprofen and polyvinyl alcohol-based mesh structured
films loaded with paracetamol were printed [112]. Taste-
masking was introduced by printing a single or double taste-
masking layer consisting of a mixture of polyethylene oxide
and strawberry mixture on top of the ODFs containing para-
cetamol. The additional taste-masking layers resulted in
a significantly slower drug release than the single layer ODF
without an additional layer printed on top. Another approach
to achieve taste-masking of ODFs or FDM 3D-printed dosage
forms, in general, is to select polymers with taste-masking
properties (for example maltodextrin [113]) as starting mate-
rial when performing the HME. In this way, no additional
coating of the ODF is needed. FDM 3D-printed aripiprazole-
loaded PVA-based ODFs has also been produced [114].
Amorphization of the poorly water-soluble drug aripiprazole
during the HME or printing step combined with the porous-
printed structure of the ODF resulted in improved dissolution
rates of the drug as compared to solvent cast films.
Some FDM printability issues of HME filaments have been
reported. To ensure successful printing and excellent content
uniformity of the printed dosage form, the diameter and
dimensional consistency of the filaments is of great impor-
tance and needs to be in the specific range stated by the
manufacturer of the printer. Other examples of identified
important filament parameters are filament stiffness, brittle-
ness, softness, moisture content, as well as melt rheology of
the filament [111,115,116]. To overcome the difficulties faced
with producing API-containing filaments by HME, Musazzi
et al. modified a commercial FDM 3D printer to a hot-melt
ram-extrusion 3D printer. Exploiting the hot-melt ram-
extrusion 3D printer the drug/polymer/plasticizer blend can
directly be fed into the FDM printer overcoming the need of
a pre-made filament. Maltodextrin-based ODFs loaded with
paracetamol were produced taking advantage of this
setup [113].
In SSE 3D printing, the 3D object is formed by extruding
a semi-solid material (e.g. pastes and gels) either by pressurized
air, syringe plunger or by a rotating screw gear through the
nozzle onto the build plate. SSE 3D printing can be used to
prepare dosage forms with a high drug load [111]. An additional
advantage of SSE compared to FDM is that the operation proce-
dure can be performed at low temperatures. Therefore, also
thermolabile drugs can be incorporated in oromucosal films by
this technique. As high temperature, which is required for both in
HME and FDMmay degrade thermolabile APIs and polymers. On
the other hand, a disadvantage for the SSE-based 3D printing
technology is the required drying or solidification period after
printing. SSE 3D printing has successfully been utilized to pro-
duce ODFs containing warfarin sodium in combination with the
film-forming polymer hydroxypropylcellulose [117]. A recent
example in the literature compares direct SSE printing of drug-
loaded warfarin films to inkjet dispensed ink onto substrates and
manual compounding of sachets [118].
In Table 2 examples of oromucosal films prepared with
printing techniques are shown.
4. Conclusion
Oromucosal films are considered a class of patient-centric
dosage forms suitable for patients with special needs, such
as children or older patients suffering from dysphagia. Patient
acceptability can be optimized by the design of the dosage
form. Stickiness, disintegration time and user friendliness are
important parameters for patient acceptance.
ODFs are predominately used in the treatment of systemic
disorders, whereas MBFs are used in the treatment of local as
well as systemic disorders. The incorporation of poorly water-
soluble drugs into oromucosal films may be challenging.
However, the reduction of particle size may improve solubility.
Recently, oromucosal films (multilayer) with prolonged release
have been developed. These tailor-made films may, due to less
frequent dosing, increase patient adherence and compliance.
A relatively new application path with potential is drug
delivery over the oral mucosa for small molecule drugs as
well as biopharmaceuticals. Via this route, the hepatic first-
pass metabolism is largely bypassed, which may lead to an
increased bioavailability.
Newly applied preparations methods are printing techni-
ques (inkjet printing, flexographic printing, and 3D printing).
Up to date inkjet printing is the most used technique.
5. Expert opinion
Oromucosal films are a relatively new addition to the arsenal
of pharmaceutical dosage forms for personalized medicine.
Nowadays there is broad focus on increasing the patient
acceptance of oromucosal films by developing better
formulations.
Medication for the treatment of certain local and systemic
disorders, such as oral inflammatory disorders, cardiovascular
disorders, and disorders of the central nervous system, can be
administered via both MBFs and ODFs, with immediate as well
as prolonged release characteristics. The latter will improve
patient compliance and adherence due to a lower dosing
frequency. The APIs are swallowed or will penetrate the buccal
mucosa. In case of the latter, an increased bioavailability may
be obtained by the addition of penetration enhancers.
Sufficient mucoadhesion is, however, a precondition for buccal
absorption.
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Oromucosal films are potential dosage forms for vaccine and
protein delivery. Both mucosal and systemic immunity can be
obtained due to the richness of antigen-presenting cells and
mucosal-associated lymphoid tissue like tonsils, salivary glands,
Waldeyer’s ring, and pharyngeal lymphoid tissue is present in
the oral cavity. This would benefit patients who suffer from
needle phobia and would avoid the use of contaminated nee-
dles, as may be the case in developing countries. Attention
should be paid to the stability of the biopharmaceutical during
preparation and storage of the oromucosal films. The addition of
vaccine in dry state circumvents stability issues. Also, the addi-
tion of biopharmaceutical stabilizers (sugars such as trehalose
and inulin) could solve this problem. In terms of production
methods, conventional solvent casting as well as novel printing
techniques can be used, but the temperature should be care-
fully monitored during production.
Although water is not required for the intake of oromucosal
films, a suitable application device would simplify the place-
ment on the tongue or attachment to the mucosa. Especially if
caregivers administer the oromucosal films to patients who
are unable to take medication, for example at late-stage
Parkinson’s disease, or for the removal of a non-dissolving
backing layer from the buccal mucosa. This application device
may be a pair of tweezers comparable to those used to
remove a soft contact lens from a storage case. An application
device would also be favorable in terms of hygiene.
The conventional preparation technique for oromucosal
films is the solvent casting technique. This technique has
some limitations, such as trial and error adjustments of the
wet film thickness or concentration of the polymer solutions.
With printing techniques, these limitations are tackled. In
addition, a precise amount of API can be printed per dosage
unit and it is feasible to print fixed API combinations.
However, challenges such as increased dosing remain. This
makes the oromucosal films especially interesting for the
administration of potent (and thus low dosed) APIs, for exam-
ple for the treatment of cardiovascular disorders, disorders of
the central nervous system, schizophrenia and migraine.
New preparation techniques introduce new requirements
for oromucosal film preparation. Solubility, dissolution, unifor-
mity of content and handling properties may significantly be
influenced by crystallization behavior of the APIs after deposi-
tion on substrate. In inkjet printing, the droplet volume is
influenced by the viscosity of the printable fluid. Most of the
3D printing techniques are not suitable for thermolabile APIs
as elevated temperatures are often used.
Nonetheless, a huge advantage of printing technique is the
possibility to integrate safety features in the form of QR codes
with the dosage form.
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